Lasofoxifene

Lasofoxifene

Identifiers
IUPAC name (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
CAS Number	180916-16-9
PubChem CID	216416
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C28H31NO2
Molar mass	413.55 or 563.64 (with tartrate)

WikiDoc Resources for Lasofoxifene
Articles
Most recent articles on Lasofoxifene Most cited articles on Lasofoxifene Review articles on Lasofoxifene Articles on Lasofoxifene in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Lasofoxifene Images of Lasofoxifene Photos of Lasofoxifene Podcasts & MP3s on Lasofoxifene Videos on Lasofoxifene
Evidence Based Medicine
Cochrane Collaboration on Lasofoxifene Bandolier on Lasofoxifene TRIP on Lasofoxifene
Clinical Trials
Ongoing Trials on Lasofoxifene at Clinical Trials.gov Trial results on Lasofoxifene Clinical Trials on Lasofoxifene at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Lasofoxifene NICE Guidance on Lasofoxifene NHS PRODIGY Guidance FDA on Lasofoxifene CDC on Lasofoxifene
Books
Books on Lasofoxifene
News
Lasofoxifene in the news Be alerted to news on Lasofoxifene News trends on Lasofoxifene
Commentary
Blogs on Lasofoxifene
Definitions
Definitions of Lasofoxifene
Patient Resources / Community
Patient resources on Lasofoxifene Discussion groups on Lasofoxifene Patient Handouts on Lasofoxifene Directions to Hospitals Treating Lasofoxifene Risk calculators and risk factors for Lasofoxifene
Healthcare Provider Resources
Symptoms of Lasofoxifene Causes & Risk Factors for Lasofoxifene Diagnostic studies for Lasofoxifene Treatment of Lasofoxifene
Continuing Medical Education (CME)
CME Programs on Lasofoxifene
International
Lasofoxifene en Espanol Lasofoxifene en Francais
Business
Lasofoxifene in the Marketplace Patents on Lasofoxifene
Experimental / Informatics
List of terms related to Lasofoxifene

Lasofoxifene (INN) (proposed tradename Fablyn) is a selective estrogen receptor modulator (SERM) which is under development for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy.

In September 2005, Pfizer Inc. received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (Oporia®), a selective estrogen receptor modulator for the prevention of osteoporosis.

On January 2008, Ligand Pharmaceuticals, through its marketing partner, Pfizer, submitted a New Drug Application for lasofoxifene, which is now to be marketed under the tradename Fablyn.

External links

• a general site dedicated to lasofoxifene